Literature DB >> 28450817

The Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders.

Brian P Ciampa1, Emmanuel Reyes Ramos1, Marie Borum1, David B Doman1.   

Abstract

In addition to drugs approved by the US Food and Drug Administration (FDA) that treat, cure, or mitigate disease, medical foods are a tool to help manage chronic conditions and diseases. A medical food, according to the FDA, is a food that is developed to be eaten or administered enterally under the guidance of a physician and that is meant for the specific dietary management of a condition or disease for which distinctive nutritional requirements, based upon known scientific principles, are established by medical evaluation. A variety of medical foods exist to help manage a wide range of medical conditions, from Alzheimer disease to HIV-associated enteropathy. EnteraGam contains serum-derived bovine immunoglobulin/protein isolate, which has been studied extensively in diarrhea-predominant irritable bowel syndrome, inflammatory bowel disease (IBD), and HIV-associated enteropathy. VSL#3 is a probiotic that is used in pouchitis for patients with ulcerative colitis as well as irritable bowel syndrome. Modulen IBD is a whole-protein, sole-nutrition formulation used to manage the active phase of Crohn's disease. Vivonex is an elemental diet that is used in a variety of diseases associated with severe gastrointestinal dysfunction. Medical foods are safe and must have proven efficacy in helping to manage a variety of gastrointestinal conditions and diseases. These therapies represent tools that can be used prior or in addition to traditional medical therapies. This article discusses the history and development of medical foods under the FDA and concentrates specifically on medical foods used to help manage diseases of the gastrointestinal tract.

Entities:  

Keywords:  EnteraGam; Medical foods; Modulen IBD; VSL#3; Vivonex

Year:  2017        PMID: 28450817      PMCID: PMC5402682     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  61 in total

1.  Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome.

Authors:  G C Parkes; N B Rayment; B N Hudspith; L Petrovska; M C Lomer; J Brostoff; K Whelan; J D Sanderson
Journal:  Neurogastroenterol Motil       Date:  2011-11-09       Impact factor: 3.598

2.  Complete remission of severe scleritis and psoriasis in a patient with active Crohn's disease using Modulen IBD as an exclusive immunomodulating diet.

Authors:  John K Triantafillidis; Gerasimos Mantzaris; Asteria Stamataki; Katerina Asvestis; Georgios Malgarinos; Aristofanis Gikas
Journal:  J Clin Gastroenterol       Date:  2008 May-Jun       Impact factor: 3.062

3.  Early enteral feeding for burned patients--an effective method which should be encouraged in developing countries.

Authors:  Nguyen Nhu Lam; Nguyen Gia Tien; Chu Manh Khoa
Journal:  Burns       Date:  2007-09-04       Impact factor: 2.744

4.  Experience with an elemental diet (Vivonex).

Authors:  J W Villaveces; D C Heiner
Journal:  Ann Allergy       Date:  1985-12

Review 5.  Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.

Authors:  L Caradonna; L Amati; T Magrone; N M Pellegrino; E Jirillo; D Caccavo
Journal:  J Endotoxin Res       Date:  2000

6.  Association between dietary fat content and outcomes in pediatric burn patients.

Authors:  Jong O Lee; Gerd G Gauglitz; David N Herndon; Hal K Hawkins; Stefanie C Halder; Marc G Jeschke
Journal:  J Surg Res       Date:  2010-11-04       Impact factor: 2.192

7.  Effect of a low fat elemental diet on pancreatic secretion during pancreatitis.

Authors:  R G Keith
Journal:  Surg Gynecol Obstet       Date:  1980-09

8.  Comparative effects of Criticare HN and Vivonex HN in the treatment of malnutrition due to pancreatic insufficiency.

Authors:  S M Nasrallah; D M Martin
Journal:  Am J Clin Nutr       Date:  1984-02       Impact factor: 7.045

9.  Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis.

Authors:  Houssam E Mardini; Alla Y Grigorian
Journal:  Inflamm Bowel Dis       Date:  2014-09       Impact factor: 5.325

Review 10.  The role of enteral nutrition in patients with inflammatory bowel disease: current aspects.

Authors:  John K Triantafillidis; Costas Vagianos; Apostolos E Papalois
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

View more
  2 in total

Review 1.  Diabetes and the Small Intestine.

Authors:  Jonathan Gotfried; Stephen Priest; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

2.  A study on food-medicine continuum among the non-institutionally trained siddha practitioners of Tiruvallur district, Tamil Nadu, India.

Authors:  S Esakkimuthu; S Sylvester Darvin; S Mutheeswaran; M Gabriel Paulraj; P Pandikumar; S Ignacimuthu; N A Al-Dhabi
Journal:  J Ethnobiol Ethnomed       Date:  2018-06-28       Impact factor: 2.733

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.